- Clareon Toric, a glistening-free* toric intraocular lens
with exceptional clarity and unrivaled stability, is rolling out
across select practices in the U.S.1-5
- Alcon digital innovations, including the newly available
Fidelis Virtual Reality Ophthalmic Surgical Simulator and patient
engagement tools, will be at showcased at booth #3926
- Vivity IOL Registry study demonstrates extended range of
vision while maintaining a low visual disturbance profile in
cataract patients
Regulatory News:
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, announced today new product
launches in the U.S. as well as activities taking place at the
upcoming American Academy of Ophthalmology (AAO) 2022 annual
meeting in Chicago.
Alcon introduces Clareon Toric IOL at AAO and completes the
Clareon Collection With the introduction of Clareon®
Toric intraocular lens (IOL), Alcon offers a robust portfolio of
options for U.S. cataract patients with astigmatism on its latest,
glistening-free* material.1-3 Clareon Toric features unique and
proven STABLEFORCE® Haptics technology, with demonstrated superior
rotational and axial stability when compared to TECNIS† and
enVista.4,5†**
Clareon Toric and Clareon Monofocal consistently deliver a broad
refractive landing zone, providing functional intermediate vision
while maintaining the expected 20/20 visual acuity at distance.6-8
The Clareon Collection of IOLs is now complete and includes Clareon
Monofocal, Clareon Toric, Clareon PanOptix®, Clareon PanOptix
Toric, Clareon Vivity® and Clareon Vivity Toric—all available in
UV-absorbing and blue light filtering foldable options in the
U.S.
“When deciding which lens to recommend to my patients, I like to
have a toolbox of versatile options that provide consistent,
predictable outcomes—and the Clareon Collection of IOLs offers
exactly that,” said Kerry Solomon, MD.§ “Now, with the availability
of Clareon Toric, I am able to offer my patients a
glistening-free,* astigmatism-correcting option for them during
surgery.”
Expanding Alcon’s digital offerings with Fidelis, and patient
engagement Fidelis™ Virtual Reality Ophthalmic Surgical
Simulator, which was introduced in select markets in May, is now
available for pre-order for customers in the U.S. Fidelis offers a
high-fidelity, virtual operating room environment with haptic
feedback to simulate the look and feel of cataract surgery, helping
new surgeons hone their skills.9,10
“Partnering with ophthalmologists to develop world-class
solutions that help drive optimal outcomes is in our DNA—and we
would not be able to deliver digital innovations without these
trusted relationships,” said Sergio Duplan, Region President Alcon
North America. “At AAO, we are proud to showcase our cloud-based
connected technologies with ARGOS®, the fastest growing biometer in
the U.S., as well as other key offerings like a text-driven patient
engagement tool with demonstrable ROI for ophthalmology practices.”
11,12
The need for remote, digital solutions in ophthalmology has
never been greater, given worldwide surgery backlogs and staffing
shortages. Alcon is committed to shaping digital transformation in
ophthalmology. In addition to the opportunity to demo Fidelis,
surgeons will be able to experience and sign up for a resource that
educates cataract patients about surgery and advanced technology
IOL options via SMS text. These activities will take place at Alcon
booth #3926 at the AAO exhibit hall, on Oct. 1-3 from 9:00
a.m.–5:00 p.m. Central Time.
Data highlight benefits of Alcon surgical ophthalmic
products Key studies being presented on Alcon products
include:
- Global registry data in more than 750 patients surrounding
AcrySof® IQ Vivity® IOL supports continued patient satisfaction,
low instances of visual disturbances and reduced spectacle
dependence.13
- Results from a multicenter, prospective clinical trial
demonstrates energy and surgical time savings when using the
CENTURION® phacoemulsification system with Active Sentry®.14
- A novel retina imaging technique using the NGENUITY® 3D
Visualization System unveiled by surgeons seeking to develop more
efficient methods for fluorescein angiography.15
- A clinical study of 500 eyes comparing results of CONTOURA®
Laser Vision Correction with Phorcides Analytic Engine in low
versus high myopia.16
To learn more about Alcon news, events and data taking place
during AAO, please visit MyAlconatAAO.com.
About Clareon IOLs and Delivery
Systems The family of Clareon intraocular lenses (IOLs)
includes the Clareon Aspheric Hydrophobic Acrylic and Clareon
Aspheric Toric IOLs, the Clareon PanOptix Trifocal Hydrophobic IOL,
Clareon PanOptix Toric, Clareon Vivity Extended Vision Hydrophobic
Posterior Chamber IOL and Clareon Vivity Toric IOLs. Each of these
IOLs is indicated for visual correction of aphakia in adult
patients following cataract surgery. In addition, the Clareon Toric
IOLs are indicated to correct pre-existing corneal astigmatism at
the time of cataract surgery. The Clareon PanOptix lens mitigates
the effects of presbyopia by providing improved intermediate and
near visual acuity while maintaining comparable distance visual
acuity with a reduced need for eyeglasses, compared to a monofocal
IOL. The Clareon Vivity lens mitigates the effects of presbyopia by
providing an extended depth of focus. Compared to an aspheric
monofocal IOL, the lens provides improved intermediate and near
visual acuity while maintaining comparable distance visual acuity.
All of these IOLs are intended for placement in the capsular bag.
Careful preoperative evaluation and sound clinical judgment should
be used by the surgeon to decide the risk/benefit ratio before
implanting any IOL in a patient with any of the conditions
described in the Directions for Use that accompany each IOL. Prior
to surgery, physicians should provide prospective patients with a
copy of the Patient Information Brochure available from Alcon,
informing them of possible risks and benefits associated with these
IOLs. Reference the Directions for Use labelling for each IOL for a
complete listing of indications, warnings and precautions.
About The Alcon Experience
Academy The Alcon Experience Academy is the umbrella for
Alcon’s industry-leading training for Eye Care Professionals,
supporting staff, residents and students – whether in person,
online or through other hands-on experiential learning
opportunities. The Alcon Experience Academy offers thousands of
courses every year, from immersive virtual reality training and
online educational courses, to in-person training at Alcon
Experience Centers worldwide. The Alcon Experience Academy website
provides training and education resources on disease states, as
well as the latest advancements in techniques and approaches for
the safe and effective use of Alcon technology.
About ARGOS® Biometer with Image
Guidance ARGOS is a non-invasive, non-contact biometer
based on swept source optical coherence tomography (SS-OCT). The
device is intended to acquire ocular measurements as well as
perform calculations to determine the appropriate intraocular lens
(IOL) power and type for implantation during intraocular lens
placement. Please refer to the ARGOS User Manual for a complete
description of proper use and maintenance, optical and technical
specifications, as well as a complete list of warnings and
precautions.
About AcrySof® IQ Vivity®
IOL The non-diffractive AcrySof® IQ Vivity® Extended
Vision Posterior Chamber Intraocular Lens Model DFT015 (referred to
as AcrySof® IQ Vivity® IOL) is a UV-absorbing and blue
light-filtering foldable intraocular lens (IOL). This IOL, compared
to a monofocal IOL, provides an extended range of vision from
distance to near without increasing the incidence of visual
disturbances.
Potential side effects: As with any surgery, there is an
implicit risk, whether or not the IOL is implanted. The
complications of the IOL implantation surgery ranges from minor
side effects (usually temporary) to serious complications. Patients
with previous illnesses or disorders (such as chronic infections of
the eye or eyelids, or diabetes) may present a higher risk of
complications. Temporary surgical complications include, but are
not limited to, reactions to medications such as irritation or mild
allergic response, bleeding, redness, itching of the eye,
sensitivity to light, swelling, corneal edema (swelling of the
cornea), problems with the iris, cell growth in the IOL, and an
increase temporary eye pressure. There is a small risk of needing
further surgical treatment (such as IOL replacement implanted by a
different one or surgery to improve vision) after the implantation
of the initial IOL.
About CENTURION® Vision
System The CENTURION® Vision System is indicated for
emulsification, separation, irrigation, and aspiration of
cataracts, residual cortical material and lens epithelial cells,
vitreous aspiration and cutting associated with anterior
vitrectomy, bipolar coagulation, and intraocular lens injection.
Appropriate use of CENTURION® Vision System parameters and
accessories is important for successful procedures. Please refer to
the ORA SYSTEM® Operator’s Manual for a complete description of
proper use and maintenance, as well as a complete list of
contraindications, warnings and precautions.
About NGENUITY® 3D Visualization
System The NGENUITY 3D Visualization System consists of
a 3D stereoscopic, high-definition digital video camera and
workstation to provide magnified stereoscopic images of objects
during micro-surgery. It acts as an adjunct to the surgical
microscope during surgery displaying real-time images or images
from recordings. Please refer to the User Manual for a complete
list of appropriate uses, warnings and precautions.
About Alcon Alcon helps
people see brilliantly. As the global leader in eye care with a
heritage spanning over 75 years, we offer the broadest portfolio of
products to enhance sight and improve people’s lives. Our Surgical
and Vision Care products touch the lives of more than 260 million
people in over 140 countries each year living with conditions like
cataracts, glaucoma, retinal diseases and refractive errors. Our
more than 24,000 associates are enhancing the quality of life
through innovative products, partnerships with Eye Care
Professionals and programs that advance access to quality eye care.
Learn more at www.alcon.com.
* Defined as modified Miyata grade 0, <25mv/mm2over 3 years
(n=138), and over 9 years (n=20), respectively. ** Compared in
vitro with enVista† and TECNIS† (n=10 lenses per group, P<0.05).
† Trademarks are the property of their respective owners. § Dr.
Solomon is a paid Alcon consultant.
References
- Werner L, Thatthamla I, Ong M, et al. Evaluation of clarity
characteristics in a new hydrophobic acrylic IOL. J Cataract
RefractSurg. 2019;45:1490-1497.
- Oshika T, Fujita Y, Inamura M, Miyata K. Mid-term and long-term
clinical assessments of a new 1-piece hydrophobic acrylic IOL with
hydroxyethyl methacrylate. J Cataract Refract Surg. 2020
May;46(5):682-687.
- Maxwell A, Suryakumar R. Long-term effectiveness and safety of
a three-piece acrylic hydrophobic intraocular lens modified with
hydroxyethyl-methacrylate: an open-label, 3-year follow-up study.
Clin Ophthalmol. 2018;12:2031-2037.
- Alcon Data on File, 2017.
- Lane S, Collins S, Das KK, Maass S, Thatthamla I, Schatz H, Van
Noy S, Jain R. Evaluation of intraocular lens mechanical stability.
J Cataract Refract Surg. 2019 Apr;45(4):501-506.
- Clareon® Vivity® Toric Directions for Use.
- Bala C, Poyales F, Guarro M, et al. Multi-country clinical
outcomes of a new nondiffractive presybopia-correcting intraocular
lens. Journal of Cataract and refractive surgery published ahead of
print DOI: 10.1097/j.jcrs.0000000000000712.
- Varma, Devesh, et. al. Clinical outcomes of a new
non-diffractive presbyopia-correcting intraocular lens from two
large confirmatory studies. American Academy of Ophthalmology.
Abstract: PA005.
- Skou Thomsen A, Bach-Holm D, Kjaerbo H, et al. Operating Room
Performance Improves After Proficiency-Based Virtual Reality
Cataract Surgery Training. National Institute of Health. 2017
April. Doi: 10.1016/j.ophtha.2016.11.015.Epub 2016 Dec 22. PMID:
28017423. Available at:
https://pubmed.ncbi.nlm.nih.gov/28017423/.
- Alcon Data on File, 2022.
- Alcon Data on File, 2022.
- Alcon Data on File, 2022.
- Srinivasan, Sathish, MBB. Patient-Reported outcomes and Visual
Performance From Real-World Registry Study With a Novel
Wavefront-Shaping EDOF IOL. AAO, Chicago, IL. 1 October 2022.
- Brézin, Antoine, MD. Evaluation of a Phacoemulsification
Handpiece With A Built-in Fluidics Pressure Sensor: The SASCA
Multicenter Study. AAO, Chicago, IL. 1 October 2022.
- Franklin, Alan, MD. FA-Enhanced Visualization During Vitrectomy
for Retinal Vascular Disease. AAO, Chicago, IL. 1 October
2022.
- Shah, Nita, MBBS. Clinical Study of 500 Eyes Comparing Results
with Contoura Laser Vision Correction (LVC) with Phorcides Analytic
Engine in Low versus High Myopia. AAO, Chicago, IL. 1 October
2022.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220929005210/en/
Investor Relations Daniel
Cravens Allen Trang + 41 589 112 110 (Geneva) + 1 817 615 2789
(Fort Worth) investor.relations@alcon.com Media Relations Melanie McCoy + 1 817 363 1247
+ 1 682 304 8657 Melanie.McCoy@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Alcon (NYSE:ALC)
Historical Stock Chart
Von Apr 2023 bis Apr 2024